Boston Scientific SEC filings, summarized
We read every Boston Scientific 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track BSX in your inbox
Add Boston Scientific to your watchlist — free, every morning.
Recent filings
Boston Scientific names Joseph Fitzgerald COO and reorganizes business segments
Boston Scientific appointed Joseph M. Fitzgerald executive vice president and chief operating officer, effective January 1, 2027, overseeing global…
Boston Scientific names Joe Fitzgerald COO and reshapes operating structure
Boston Scientific appointed Joseph M. Fitzgerald executive vice president and chief operating officer effective January 1, 2027, with responsibility for…
Boston Scientific executive Arthur Butcher to retire effective January 1
Arthur C. Butcher will retire as Boston Scientific’s executive vice president and group president of MedSurg and Asia Pacific effective January 1, 2027. He…
Boston Scientific Reports Cybersecurity Incident Disrupting Global Operations
Boston Scientific said it identified a cybersecurity incident on August 25, 2026, affecting certain information technology systems and causing global…
Boston Scientific director Susan Morano buys $100,408 in stock
Boston Scientific director Susan E. Morano bought 2,040 shares of common stock in an open-market transaction on Aug. 25 at $49.22 per share, for an…
Boston Scientific CEO Michael Mahoney buys $9.0M in stock
Michael F. Mahoney, Boston Scientific’s Chairman, President, CEO and director, purchased 186,240 shares of common stock on Aug. 3 at $48.33 per share, for…
Boston Scientific director Edward Ludwig buys $227,400 in stock
Boston Scientific director Edward J. Ludwig purchased 5,000 shares in an open-market transaction at $45.48 per share on July 31, 2026, for approximately…
Boston Scientific reports 7.5% second-quarter sales growth and raises full-year EPS outlook
Boston Scientific reported second-quarter 2026 net sales of $5.442 billion, up 7.5% year over year, with GAAP diluted EPS of $0.61 and adjusted EPS of…
Boston Scientific approves restructuring plan with up to $800 million in charges
Boston Scientific’s board approved a global restructuring plan on July 21, 2026, involving supply-chain changes, production-line transfers, organizational…
8‑K (Item 9.01): Boston Scientific ($BSX) on Feb 26, 2026 filed three credit agreements — two Credit…
8‑K (Item 9.01): Boston Scientific ($BSX) on Feb 26, 2026 filed three credit agreements — two Credit Agreements (Exs. 10.1 & 10.2) and a Term Loan Credit…
Boston Scientific ($BSX) 8-K filed 2026-02-26: Item 2.03 confirms creation of a direct financial…
Boston Scientific ($BSX) 8-K filed 2026-02-26: Item 2.03 confirms creation of a direct financial obligation / off‑balance‑sheet arrangement via the 2026…
Boston Scientific ($BSX) terminated its prior 2021 Revolving Credit Agreement on Feb 26, 2026 after…
Boston Scientific ($BSX) terminated its prior 2021 Revolving Credit Agreement on Feb 26, 2026 after entering a new 2026 Revolving Credit Agreement. Prior…
BREAKING: $BSX secures an $11B credit package to fund the Penumbra acquisition & bolster liquidity — $3B…
BREAKING: $BSX secures an $11B credit package to fund the Penumbra acquisition & bolster liquidity — $3B revolver + $2B 364‑day revolver + $6B delayed‑draw…
8‑K filed 2/23/2026: Boston Scientific attached Exhibit 99.1 (press release dated Feb 23, 2026) and…
8‑K filed 2/23/2026: Boston Scientific attached Exhibit 99.1 (press release dated Feb 23, 2026) and Exhibit 104 (iXBRL cover page). Routine Item 9.01 filing…
On Feb 18, 2026 Boston Scientific's Board approved a $4.0B increase to its repurchase authorization,…
On Feb 18, 2026 Boston Scientific's Board approved a $4.0B increase to its repurchase authorization, bringing the program to $5.0B total (previously $1.0B).…
Boston Scientific ($BSX) appointed Ms.
Boston Scientific ($BSX) appointed Ms. Smith and Mr. Weber to its Board; press release issued Feb 23, 2026 and furnished as Exhibit 99.1 to the Form 8‑K.…
Boston Scientific ($BSX) increased its Board from 10 to 12 and appointed Catherine R.
Boston Scientific ($BSX) increased its Board from 10 to 12 and appointed Catherine R. Smith and Christophe P. Weber, effective Feb 18, 2026. Company says…
Boston Scientific ($BSX) says director Yoshiaki Fujimori told the company on Feb 2, 2026 he will not stand…
Boston Scientific ($BSX) says director Yoshiaki Fujimori told the company on Feb 2, 2026 he will not stand for re‑election at the 2026 Annual Meeting. He’s…
Boston Scientific filed an 8‑K on Feb 4, 2026 furnishing a press release (Exhibit 99.1) — press release…
Boston Scientific filed an 8‑K on Feb 4, 2026 furnishing a press release (Exhibit 99.1) — press release dated Feb 4, 2026. Investors: review the PR for any…
Boston Scientific ($BSX) issued a press release on Feb 4, 2026 announcing financial results for the fourth…
Boston Scientific ($BSX) issued a press release on Feb 4, 2026 announcing financial results for the fourth quarter and full year ended Dec 31, 2025. Release…